Santaris, Bristol-Myers partner to develop RNA-targeted medicines
Santaris’ proprietary Locked Nucleic Acid (LNA) drug platform will be used in the discovery and development of the novel medicines. The LNA Drug platform combines the company’s LNA
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.